Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder

• Status: Completed
• Trial end date: 2001-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

Our study aims at contributing to a valid appraisal of the magnitude of naltrexone efficacy as an antidissociative agent by using a double-blind randomized controlled trial.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Central Institute of Mental Health, Mannheim
• Collaborator: University of Freiburg
• Treatments: Naltrexone

Criteria

Inclusion Criteria:

• Diagnosis of BPD according to DSM-IV

• DES score ≥ 18

• Female gender

• Age between 18 and 50 years

Exclusion Criteria:

• Lifetime diagnosis of schizophrenia, psychotic or delusional disorder

• Current major depressive episode

• Lifetime diagnosis opioid dependence

• Current diagnosis opioid abuse

• Liver insufficiency or hepatitis

• Other major medical or neurological medical condition

• Pregnancy or lactation

• Psychotropic medication within two weeks before and during the trial (fluoxetine 4 weeks, lithium 8 weeks)

• Concomitant treatment with opioid analgetics

• Hypersensitivity to naltrexone